Biointelect provides a range of services for biopharmaceutical and medical device companies seeking to commercialise new technologies globally. We conduct detailed market evaluations and we define optimum clinical, regulatory, reimbursement and market-entry strategies.

For early stage companies we provide commercial and market insights to support product development. We can also assist with portfolio prioritisation grant applications and helping you get investor or partner ready.
For late stage companies, we have a proven track record in new product planning, market access and identifying the right stakeholders, the policy context and evidence gaps. For investors, our industry expertise supports your investment decisions and helps your portfolio companies reach their next value inflection point.

Supporting Early Stage Technologies with Commercialisation

We support early stage biotechnology and medical technology companies and research groups by navigating their technology development, evaluating path to market and helping them get grant ready, partner ready and investor ready.

  • Comprehensive market analysis, including size of addressable market, refining/generating target product profile, validating value proposition and competitive landscape
  • High level product development plan that articulates your regulatory strategy, path to market, needed studies with costs and timelines
  • Generation of pitch deck for presentation to investors, including comprehensive market assessment and revenue projections
  • Assistance with grants and commercialisation business cases, to clearly identify all milestones, timelines and how to achieve each milestone
  • Financial modelling: building  revenue models for key markets (domestic and international), as well as cost models based on product development plan

Policy, Healthcare Environment and Industry Engagement

Biointelect partners with industry, government and not-for-profit clients to enable the therapeutic sector to better improve patient outcomes.

  • Our team have a successful track record of working with governments to find policy solutions that are workable
  • We know the therapeutic industry and can effectively engage with them to find solutions
  • We bring a unique 360° view that takes into account all components of therapeutic development in policy discussions

Please see the white papers on our resources page as examples of our work.

Supporting Investors & Portfolio Companies

Biointelect can support your team with additional capacity to accelerate your review of external opportunities. We also bring our combined industry expertise and track record to add an independent view on opportunities.

Financial modelling

  • Revenue forecasting and pricing analysis
  • Analysis of product development and commercialisation costs
  • Valuation models to identify key drivers of value and financial risk

Due Diligence

  • Technical and commercial due diligence for when you lack capacity or therapeutic area expertise
  • Access to an extensive expert network
  • Independent position

Validate the market

  • Provide an external view on market potential and competitive landscape
  • Interrogate the assumptions behind the revenue projections based on real life experience
  • Provide regulatory and market access insights
  • Identify risks

New Product Planning and Market Access Strategy

We have a successful international track record in developing or localising the new product planning activities.

Whether your team requires extra capacity to address internal constraints, or a “reality check” to validate internal assumptions, we provide strategic and actionable insights for key decisions in your company.

We bring a unique 360° view that takes into account all components of market entry.

  • Size of the patient population, map current and future treatment algorithms as well as market and competitive dynamics
  • Develop adaptive, flexible forecast (epidemiological/patient or prescription-based models) in a user-friendly Excel format allowing sensitivity analysis around key variables impacting the forecast
  • Advice on policy & reimbursement contexts and gaps related to all aspects of the value proposition, new product planning, HTA and market access; Undertaking of policy and advocacy work associated with addressing these contexts and gaps
  • Advice on clinical trial design and incorporation of optimal outcomes endpoints, KOL engagement and advisory boards
  • Optimization of available outcomes data to support value propositions and dossier development
  • Assistance with engagement of patient advocates to understand and present patient-relevant outcomes